8 Product-Hopping Takeaways From Namenda Ruling

Law360, New York (June 11, 2015, 9:18 AM EDT) -- On May 22, 2015, in New York v. Actavis,[1] a panel of the U.S. Court of Appeals for the Second Circuit became the first appellate court to consider the legal limits attendant to “product-hopping” in the pharmaceutical industry, a term given by some to a variety of practices used by drug manufacturers to migrate patients from a medicine approaching the end of its patent life to a successor with much of its patent term remaining.

In affirming the district court’s grant of a preliminary injunction, the panel held that pharmaceutical manufacturer Actavis PLC, and its wholly owned subsidiary Forest Laboratories LLC...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS